This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Actinomycosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Actinomycosis is rare, chronic bacterial infection which results in a slowly progressive granulomatous disease.

  • the bacteria which is a filamentous Gram positive anaerobic bacteria from the Actinomycetaceae family (genus Actinomyces) is a normal colonizing organism of the human oropharynx, gastrointestinal tract, and urogenital tract.
  • it is mainly an endogenous infection where a breech in the mucous membrane results in bacteria invading the local structures and organs and causing a disease
  • A israelii is the commonest human pathogen while less common species include A naeslundii, A odontolyticus, A viscosus, A meyeri, A turicensis, and A radingae.

Often the bacteria coexists with other normal commensals e. g - Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans), fusobacteria, bacteroides, staphylococci (including S aureus),streptococci (including β haemolytic streptococci and S pneumoniae), or Enterobacteriaceae but precise pattern of organisms depends on the site of infection (1).

The infection spreads along the fascial planes and occasionally by the blood-stream, but not via the lymphatics.

Thermophilic actinomycetes found in hay are the cause of the extrinsic allergic alveolitis termed farmer's lung.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.